Format

Send to

Choose Destination
Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Author information

1
Division of Hematology, The Ohio State University, Columbus, OH, USA.
2
The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK.
3
Stanford University School of Medicine, Stanford, CA, USA.
4
Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, Australia.
5
Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
6
Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
7
Division of Hematology/Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
8
University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
9
Sarah Cannon Research Institute, Nashville, TN, USA.
10
Medical University of Vienna, Vienna, Austria.
11
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
12
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
13
University of California Irvine, Irvine, CA, USA.

Abstract

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

KEYWORDS:

anticoagulation; bleeding; chronic lymphocytic leukaemia; haemorrhage; ibrutinib

PMID:
28397242
PMCID:
PMC6084297
DOI:
10.1111/bjh.14660
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center